Kweichow Moutai Presents Chinese Enterprise’s ESG Insights at 2025 WEF
24.1.2025 17:49:00 EET | Business Wire | Press release
Wang Li, General Manager of Kweichow Moutai Group, China's top liquor company, was invited to participate in the 2025 World Economic Forum (WEF) Annual Meeting, which officially opened recently, and shared the Moutai solutions on topics such as ESG practices, green and low-carbon development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124612942/en/
Wang Li, General Manager of Kweichow Moutai Group, presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon. (Photo: Business Wire)
At the 2025 Davos-Tencent Finance Vision Dinner, Wang explained the ESG development based on Moutai's practices. She said that Moutai adheres to long-termism and high-quality development, integrates the ESG concept into the entire production and operation process. By pursuing sustainable development from three dimensions: harmonious coexistence with nature, sharing of social value, and modernization of self-governance, Moutai accumulates momentum and advantages for future development.
Besides, Wang Li presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon as well. She said that Moutai liquor is the result of adhering to harmonious coexistence between mankind and nature. Kweichow Moutai Group insists on leveraging the innovative power of green technology to support the company's green development, focusing on "energy saving, carbon reduction, emission reduction, and efficiency improvement" to achieve "greening level improvement of the main value chain".
Through the resource utilization, greening and high-end development of the by-products in the liquor industry, Moutai has realized the utilization of its by-products. Looking to the future, Moutai will be committed to applying more innovative power and methods of green technology to maintain the characteristics of its products.
Furthermore, Wang proposed Moutai's carbon reduction solution at the First Movers Coalition Leadership Meeting. Wang said, “The accurate management of the whole chain is an important feature of Moutai's carbon emission management. Moutai accounts for the carbon footprint of the whole life cycle of its products and has formulated targeted programs for the transformation of the energy structure, the reduction and greening of packaging materials, etc.”
Moutai also pays attention to the recycling of post-drinking packages, and plans to start post-drinking package recycling in China's provincial capitals in 2025, with the goal of reducing the carbon emissions of the whole industrial chain by 20% by 2030.
During the WEF, Wang Li will also take part in the “China Night” dialogue, sharing Moutai's wisdom with Chinese and foreign experts on the thinking of Chinese enterprises in coping with the age of intelligence and the shaping of the international image of Chinese enterprises.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250124612942/en/
Contacts
Eason Zhou
Email: evisionsinfo@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom